Session Title: AMD I
Session Date/Time: Thursday 26/09/2013 | 08:30-10:30
Paper Time: 09:26
Venue: Hall 1 (Level 2)
First Author: U.Introini ITALY
Co Author(s): G. Triolo G. Casalino F. Bandello -. -
To evaluate the efficacy and safety of stereotactic radiotherapy (IRay™, Oraya) combined with Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV) treatment.
Monocentric Interventional twelve-month Pilot Study
Ten eyes of 10 patients with AMD and PCV were included. The polypoidal complex should be no closer to the optic disk than 3 mm, BCVA between 25 and 75 ETDRS letters, and axial length between 21 mm and 26 mm. At baseline, all the eyes received an intravitreal injection of Ranibizumab, followed by a single dose of 16 Gy delivered on the macular area with the IRay™ System. During monthly follow-up visits, further Ranibizumab injections were given PRN. Primary Outcomes were BCVA and Central Retinal Thickness (CRT) changes. Secondary Outcomes were mean injection number and PCV changes by means of ICGA.
At month six, mean BCVA improved by eight ETDRS letters. Mean CRT decreased by 126 mµ. Mean additional intravitreal injections were 1.9. The PCV aneurysmal bulge component was obliterated in all cases when included in the irradiation spot. No local or systemic adverse events occurred.
Our preliminary data on combined Ranibizumab and stereotactic X-ray therapy of PCV showed a mean BCVA improvement, a mean CRT decrease and aneurismal component closure. Month-12 evaluation is mandatory in order to confirm our findings.